United States Biopsy Devices Market Outlook to 2025 – Biopsy Forceps, Biopsy Guns and Needles, Biopsy Punches, Biopsy Core Needles and Devices and Others

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$4995

GlobalData’s “United States Biopsy Devices Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United States Biopsy Devices market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Biopsy Core Needles & Devices, Biopsy Disposable Vacuum-Assisted Needle Devices, Biopsy Fine Aspiration Needles & Devices, Biopsy Forceps, Biopsy Guns & Needles and Biopsy Punches.

The United States Biopsy Devices Market report provides key information and data on:
• Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2015 to 2025.
• 2019 company share and distribution share data for Biopsy Devices Market.
• Global corporate-level profiles of key companies operating within the United States Biopsy Devices Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

United States Biopsy Devices is segmented as follows:

• Biopsy Core Needles & Devices

• Biopsy Disposable Vacuum-Assisted Needle Devices

• Biopsy Fine Aspiration Needles & Devices

• Biopsy Forceps

• Biopsy Guns & Needles

• Biopsy Punches

Reasons to Buy

Key Reasons to Purchase – The United States Biopsy Devices Market report helps you to develop:

• Business strategies by identifying the key market segments poised for strong growth in the future.

• Market-entry and market expansion strategies.

• Design competition strategies by identifying who-stands-where in the market.

• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

• Understand the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Key companies covered in the “United States Biopsy Devices Market Outlook to 2025” report:
• Becton Dickinson and Co
• Hologic Inc
• Cook Medical Inc

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 6

2 Introduction 7

2.1 What Is This Report About? 7

2.2 Biopsy Devices Market Segmentation 7

2.3 Definitions of Markets Covered in the Report 8

3 Biopsy Devices Market, United States 10

3.1 Biopsy Devices Market, United States, Revenue ($m), 2015-2025 10

3.1.1 Biopsy Core Needles & Devices Market, United States, Revenue ($m), by Segment, 2015-2025 13

3.1.2 Biopsy Fine Aspiration Needles & Devices Market, United States, Revenue ($m), by Segment, 2015-2025 15

3.1.3 Biopsy Forceps Market, United States, Revenue ($m), by Segment, 2015-2025 17

3.1.4 Biopsy Guns & Needles Market, United States, Revenue ($m), by Segment, 2015-2025 19

3.1.5 Biopsy Punches Market, United States, Revenue ($m), by Segment, 2015-2025 21

3.2 Biopsy Devices Market, United States, Volume (Units), 2015-2025 23

3.2.1 Biopsy Core Needles & Devices Market, United States, Volume (Units), by Segment, 2015-2025 26

3.2.2 Biopsy Fine Aspiration Needles & Devices Market, United States, Volume (Units), by Segment, 2015-2025 28

3.2.3 Biopsy Forceps Market, United States, Volume (Units), by Segment, 2015-2025 30

3.2.4 Biopsy Guns & Needles Market, United States, Volume (Units), by Segment, 2015-2025 32

3.2.5 Biopsy Punches Market, United States, Volume (Units), by Segment, 2015-2025 34

3.3 Biopsy Devices Market, United States, Average Price ($) , 2015-2025 36

3.4 Biopsy Devices Market, United States, Distribution Share by Revenue ($m), 2019 38

3.5 Biopsy Devices Market, United States, Company Share by Revenue ($m), 2019 39

4 Overview of Key Companies in United States, Biopsy Devices Market 41

4.1 Becton Dickinson and Co 41

4.1.1 Company Overview 41

4.2 Hologic Inc 41

4.2.1 Company Overview 41

4.3 Cook Medical Inc 41

4.3.1 Company Overview 41

4.4 Medtronic Plc 42

4.4.1 Company Overview 42

4.5 Argon Medical Devices Inc 42

4.5.1 Company Overview 42

4.6 Boston Scientific Corp 42

4.6.1 Company Overview 42

4.7 Cardinal Health Inc 42

4.7.1 Company Overview 42

4.8 Merit Medical Systems Inc 43

4.8.1 Company Overview 43

4.9 ConMed Corp 43

4.9.1 Company Overview 43

4.10 Devicor Medical Products Inc 43

4.10.1 Company Overview 43

5 Biopsy Devices Market Pipeline Products 44

6 Financial Deals Landscape 46

6.1 Acquisition 46

6.1.1 Canon Acquires 70% Stake in Quality ElectroDynamics 46

6.2 Debt Offerings 47

6.2.1 Stryker Prices Public Offering of

1.15% Notes Due 2025 for USD650 Million 47

6.2.2 Stryker Prices Public Offering of

1.95% Notes Due 2030 for USD1 Billion 49

6.2.3 Stryker Prices Public Offering of

2.9% Notes Due 2050 for USD650 Million 51

6.2.4 Boston Scientific Raises USD1.2 Billion in Public Offering of

2.65% Senior Notes due 2030 53

6.2.5 Boston Scientific Raises USD500 Million in Public Offering of

1.9% Senior Notes due 2025 55

6.2.6 Stryker Raises USD826.2 Million in Public Offering of 1% Notes Due 2031 57

6.2.7 Stryker Raises USD881.3 Million in Public Offering of

0.75% Notes Due 2029 59

6.2.8 Stryker Raises USD936.4 Million in Public Offering of

0.25% Notes Due 2024 61

6.2.9 Boston Scientific Raises USD999.2 Million in Public Offering of

0.625% Notes Due 2027 63

6.3 Equity Offerings 65

6.3.1 Boston Scientific Raises USD1 Billion in Public Offering of Shares 65

6.3.2 Boston Scientific Raises USD1 Billion in Public Offering of

5.5% Mandatory Convertible Preferred Stock 67

6.3.3 iCAD Prices Private Placement of Shares for USD12.5 Million 69

6.3.4 iCAD Plans to Raise up to USD25 Million in Public Offering of Shares 70

6.3.5 iCAD Raises USD10.34 Million in Public Offering of Shares 71

6.4 Partnerships 73

6.4.1 Hatch Medical Enters into Licensing Agreement with Argon Medical Devices 73

6.5 Venture Financing 74

6.5.1 Promaxo Secures USD8 Million in Funding Round 74

6.5.2 Seer (Seer Biosciences) Secures USD17.5 Million in Series C Funding 75

7 Recent Developments 76

7.1 Corporate Communications 76

7.1.1 Mar 02, 2020: Stryker announces new Investor Relations leader 76

7.1.2 Feb 25, 2020: Stryker announces nomination of new Director, Lisa Skeete Tatum 76

7.1.3 Jan 24, 2020: Cardinal Health: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers 76

7.1.4 Jan 13, 2020: iCAD appoints Nathaniel Dalton to its board of directors 77

7.1.5 Dec 03, 2019: Dr. John Halamka named president of Mayo Clinic Platform 77

7.1.6 Nov 12, 2019: Cook Medical’s leadership updates in Asia-pacific reinforce focus on growth and physician relationships 78

7.1.7 Oct 08, 2019: CardioWise named a top-ten finalist in Best Cardiovascular Digital Diagnostic Category by UCSF Health Hub 78

7.1.8 Aug 28, 2019: Rose Kelly-Falls named global leader of procurement and supply chain for Cook Medical 79

7.1.9 Aug 19, 2019: Merit Medical announces appointment of Lynne N. Ward to its Board of Directors 79

7.1.10 Aug 12, 2019: Stryker announces commercial structure realignment 79

7.1.11 Aug 07, 2019: Dean Scarborough and John Weiland to join Cardinal Health's Board of Directors 79

7.1.12 Jul 24, 2019: Former Medtronic Executive Sean Ginney named VP of Sales at Current Health 80

7.1.13 Jul 16, 2019: Cardinal Health appoints Stephen Mason to lead medical segment 81

7.1.14 Jul 08, 2019: Cardinal Health: Departure of CFO 81

7.1.15 Jul 03, 2019: Britta Lesaux appointed president & CEO Philips Canada 82

7.2 Financial Announcements 82

7.2.1 Feb 27, 2020: iCAD reports fourth quarter and full-year 2019 financial results 82

7.2.2 Feb 24, 2020: Merit Medical reports earnings for fourth quarter and year ended December 31, 2019, gives FY 2020 Guidance 84

7.2.3 Feb 06, 2020: Cardinal Health reports second quarter results for fiscal year 2020 85

7.2.4 Feb 05, 2020: Boston Scientific announces results for fourth quarter and full year 2019 86

7.2.5 Jan 28, 2020: Stryker reports 2019 results and 2020 outlook 87

7.2.6 Jan 14, 2020: Boston Scientific announces preliminary unaudited sales for the fourth quarter and full year 2019 88

7.2.7 Jan 12, 2020: Hologic announces preliminary financial results for first quarter of fiscal 2020 89

7.2.8 Nov 07, 2019: Cardinal Health reports first quarter results for fiscal year 2020 90

7.2.9 Nov 06, 2019: Hologic announces financial results for fourth quarter of fiscal 2019 90

7.2.10 Oct 30, 2019: iCAD reports financial and operating results for the third quarter and nine months ended September 30, 2019 92

7.2.11 Oct 30, 2019: Merit Medical reports earnings for third quarter of 2019 94

7.2.12 Oct 23, 2019: Boston Scientific announces results for third quarter 2019 96

7.2.13 Aug 08, 2019: Cardinal Health reports fourth quarter and full year results for fiscal year 2019 97

7.2.14 Aug 01, 2019: iCAD reports second quarter 2019 financial results 99

7.2.15 Jul 31, 2019: Hologic announces financial results for third quarter of fiscal 2019 100

7.2.16 Jul 25, 2019: Merit Medical reports earnings for second quarter of 2019 101

7.2.17 Jul 25, 2019: Stryker reports second quarter 2019 operating results 103

7.2.18 Jul 24, 2019: Boston Scientific announces results for second quarter 2019 104

7.3 Government and Public Interest 105

7.3.1 Jan 27, 2020: Merit Medical issues statement regarding director nominations from starboard 105

7.4 Legal And Regulatory 106

7.4.1 Sep 26, 2019: TSO3 announces receipt of final Court approval for plan of arrangement with Stryker 106

7.4.2 Aug 12, 2019: Lead plaintiff deadline alert: Faruqi & Faruqi encourages investors who suffered losses exceeding $100,000 In Cardinal Health to contact the firm 106

7.5 Other Significant Developments 107

7.5.1 Apr 14, 2020: BioCardia announces litigation financing in the case captioned Boston Scientific 107

7.5.2 Mar 31, 2020: iCAD announces new credit facility with Bridge Bank, increasing operational flexibility 107

7.5.3 Feb 05, 2020: Hologic launches new scalable options for panther system in the United States and Europe 108

7.5.4 Dec 20, 2019: Cook Medical applauds congressional action to repeal the medical device excise tax 109

7.5.5 Dec 04, 2019: Study finds 'Virtual Biopsy" allows doctors to accurately diagnose precancerous pancreatic cysts 109

7.5.6 Aug 28, 2019: Boston Scientific Celebrates 15th Anniversary in Costa Rica 110

7.5.7 Jun 14, 2019: Stryker to invest €200m in RD&I projects in Ireland 110

7.6 Strategy And Business Planning 111

7.6.1 Feb 18, 2020: Hologic Expands Costa Rican operations with new financial shared services center 111

7.6.2 Jan 15, 2020: Merit milestones: facilities in Galway and Tijuana reach 1,000 employees 112

7.6.3 Dec 05, 2019: UC San Diego Launches Center for Fluorescence-Guided Surgery 112

7.6.4 Nov 05, 2019: Stryker signs agreement to acquire Wright Medical for $5.4bn 113

7.6.5 Jun 24, 2019: Boston Scientific Galway expands in to new facility 114

7.6.6 Jun 21, 2019: Hologic signs deal to buy SuperSonic Imagine 114

8 Appendix 116

8.1 Research Methodology 117

8.1.1 Coverage 117

8.1.2 Secondary Research 117

8.1.3 Primary Research 118

8.1.4 Market Modeling and Forecasting 119

8.1.5 Company Share Analysis 120

8.1.6 Distribution Share Analysis 121

8.1.7 Benchmarking 121

8.2 GlobalData Consulting 122

8.3 Contact Us 122

8.4 Disclaimer 122

Frequently asked questions

United States Biopsy Devices Market Outlook to 2025 – Biopsy Forceps, Biopsy Guns and Needles, Biopsy Punches, Biopsy Core Needles and Devices and Others thematic reports
Currency USD
$4,995

Can be used by individual purchaser only

$14,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at United States Biopsy Devices Market Outlook to 2025 – Biopsy Forceps, Biopsy Guns and Needles, Biopsy Punches, Biopsy Core Needles and Devices and Others in real time.

  • Access a live United States Biopsy Devices Market Outlook to 2025 – Biopsy Forceps, Biopsy Guns and Needles, Biopsy Punches, Biopsy Core Needles and Devices and Others dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.